Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
Status:
Completed
Trial end date:
2018-12-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the potential effectiveness of losartan (100mg
daily) for reducing inflammation and improving immune recovery.
Phase:
Phase 2
Details
Lead Sponsor:
Hennepin Healthcare Research Institute Minneapolis Medical Research Foundation